psmb5 β5 Search Results


western blot antibodies against psmb5  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology western blot antibodies against psmb5
( A ) Molecular structure of biotinylated BTZ (BTZ-b). ( B ) Flow cytometry–based apoptosis assay to examine the cytotoxicity of BTZ-b in CTR-KD versus ISG-KD (sh1) ARD cells. The cells were treated with BTZ-b (2 μM) for 24 hours. DMSO- or biotin-treated cells served as CTRs ( n = 3). Student’s t test was performed. * P ≤ 0.05. ( C ) BTZ-b pull-down assay using ARD cell lysate in the presence of BTZ to examine BTZ competition with BTZ-b in <t>PSMB5</t> binding. BTZ was added to the cell lysate to a final concentration of 200 μM and incubated with BTZ-b–coated beads for competition. ( D ) Biotinylated BTZ pull-down assay using CTR-KD and ISG-KD ARD cell lysates. Biotin served as a negative control for pull-down. The pull-down precipitate and the whole-cell lysates (input) were subjected to Western blotting. ( E ) BTZ-b pull-down assay using CTR and ISG-OE AMO1 cell lysates. ( F ) BTZ-b pull-down assay using recombinant ISG20L2 (rISG) and PSMB5 (rB5) proteins. The recombinant protein was dissolved in PBS. The final concentration of rB5 was 0.5 μg/mL (+), while the final concentration of rISG was 0.25 μg/mL (+) or 1.5 μg/mL (++). Using the gray intensity of PSMB5 pull-down by BTZ-b alone as a control, ImageJ software (NIH) was used to determine the levels of PSMB5 pull-down by BTZ-b with rISG competition. Numbers indicated on the lane. ( G ) BTZ binds to ISG20L2 as shown by SPR measurements. Graphs of equilibrium response unit (RU) responses versus compound concentrations were plotted. The estimated K D is 26.71 μM, as shown by the vertical dotted line. ( H ) Schematic mechanism of ISG20L2-induced MM BTZ resistance.
Western Blot Antibodies Against Psmb5, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psmb5+%CE%B25/20S+Proteasome+%CE%B25+Antibody/pmc09675441-135-12-35
Average 93 stars, based on 1 article reviews
western blot antibodies against psmb5 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
gene exp psmb5 rn01488741 m1  (Thermo Fisher)
85
Thermo Fisher gene exp psmb5 rn01488741 m1
( A ) Molecular structure of biotinylated BTZ (BTZ-b). ( B ) Flow cytometry–based apoptosis assay to examine the cytotoxicity of BTZ-b in CTR-KD versus ISG-KD (sh1) ARD cells. The cells were treated with BTZ-b (2 μM) for 24 hours. DMSO- or biotin-treated cells served as CTRs ( n = 3). Student’s t test was performed. * P ≤ 0.05. ( C ) BTZ-b pull-down assay using ARD cell lysate in the presence of BTZ to examine BTZ competition with BTZ-b in <t>PSMB5</t> binding. BTZ was added to the cell lysate to a final concentration of 200 μM and incubated with BTZ-b–coated beads for competition. ( D ) Biotinylated BTZ pull-down assay using CTR-KD and ISG-KD ARD cell lysates. Biotin served as a negative control for pull-down. The pull-down precipitate and the whole-cell lysates (input) were subjected to Western blotting. ( E ) BTZ-b pull-down assay using CTR and ISG-OE AMO1 cell lysates. ( F ) BTZ-b pull-down assay using recombinant ISG20L2 (rISG) and PSMB5 (rB5) proteins. The recombinant protein was dissolved in PBS. The final concentration of rB5 was 0.5 μg/mL (+), while the final concentration of rISG was 0.25 μg/mL (+) or 1.5 μg/mL (++). Using the gray intensity of PSMB5 pull-down by BTZ-b alone as a control, ImageJ software (NIH) was used to determine the levels of PSMB5 pull-down by BTZ-b with rISG competition. Numbers indicated on the lane. ( G ) BTZ binds to ISG20L2 as shown by SPR measurements. Graphs of equilibrium response unit (RU) responses versus compound concentrations were plotted. The estimated K D is 26.71 μM, as shown by the vertical dotted line. ( H ) Schematic mechanism of ISG20L2-induced MM BTZ resistance.
Gene Exp Psmb5 Rn01488741 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psmb5+%CE%B25/Gene+Exp%2E+Psmb5%2C+Rn01488741_m1/pmc03464398-63-17-2
Average 85 stars, based on 1 article reviews
gene exp psmb5 rn01488741 m1 - by Bioz Stars, 2026-09
85/100 stars
  Buy from Supplier
gene exp psmb5 rn01488742 m1  (Thermo Fisher)
93
Thermo Fisher gene exp psmb5 rn01488742 m1
( A ) Molecular structure of biotinylated BTZ (BTZ-b). ( B ) Flow cytometry–based apoptosis assay to examine the cytotoxicity of BTZ-b in CTR-KD versus ISG-KD (sh1) ARD cells. The cells were treated with BTZ-b (2 μM) for 24 hours. DMSO- or biotin-treated cells served as CTRs ( n = 3). Student’s t test was performed. * P ≤ 0.05. ( C ) BTZ-b pull-down assay using ARD cell lysate in the presence of BTZ to examine BTZ competition with BTZ-b in <t>PSMB5</t> binding. BTZ was added to the cell lysate to a final concentration of 200 μM and incubated with BTZ-b–coated beads for competition. ( D ) Biotinylated BTZ pull-down assay using CTR-KD and ISG-KD ARD cell lysates. Biotin served as a negative control for pull-down. The pull-down precipitate and the whole-cell lysates (input) were subjected to Western blotting. ( E ) BTZ-b pull-down assay using CTR and ISG-OE AMO1 cell lysates. ( F ) BTZ-b pull-down assay using recombinant ISG20L2 (rISG) and PSMB5 (rB5) proteins. The recombinant protein was dissolved in PBS. The final concentration of rB5 was 0.5 μg/mL (+), while the final concentration of rISG was 0.25 μg/mL (+) or 1.5 μg/mL (++). Using the gray intensity of PSMB5 pull-down by BTZ-b alone as a control, ImageJ software (NIH) was used to determine the levels of PSMB5 pull-down by BTZ-b with rISG competition. Numbers indicated on the lane. ( G ) BTZ binds to ISG20L2 as shown by SPR measurements. Graphs of equilibrium response unit (RU) responses versus compound concentrations were plotted. The estimated K D is 26.71 μM, as shown by the vertical dotted line. ( H ) Schematic mechanism of ISG20L2-induced MM BTZ resistance.
Gene Exp Psmb5 Rn01488742 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psmb5+%CE%B25/Gene+Exp%2E+Psmb5%2C+Rn01488742_m1/pm33010214-101-26-20
Average 93 stars, based on 1 article reviews
gene exp psmb5 rn01488742 m1 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
proteasome β5 subunit  (Cell Signaling Technology Inc)
93
Cell Signaling Technology Inc proteasome β5 subunit
( A ) Molecular structure of biotinylated BTZ (BTZ-b). ( B ) Flow cytometry–based apoptosis assay to examine the cytotoxicity of BTZ-b in CTR-KD versus ISG-KD (sh1) ARD cells. The cells were treated with BTZ-b (2 μM) for 24 hours. DMSO- or biotin-treated cells served as CTRs ( n = 3). Student’s t test was performed. * P ≤ 0.05. ( C ) BTZ-b pull-down assay using ARD cell lysate in the presence of BTZ to examine BTZ competition with BTZ-b in <t>PSMB5</t> binding. BTZ was added to the cell lysate to a final concentration of 200 μM and incubated with BTZ-b–coated beads for competition. ( D ) Biotinylated BTZ pull-down assay using CTR-KD and ISG-KD ARD cell lysates. Biotin served as a negative control for pull-down. The pull-down precipitate and the whole-cell lysates (input) were subjected to Western blotting. ( E ) BTZ-b pull-down assay using CTR and ISG-OE AMO1 cell lysates. ( F ) BTZ-b pull-down assay using recombinant ISG20L2 (rISG) and PSMB5 (rB5) proteins. The recombinant protein was dissolved in PBS. The final concentration of rB5 was 0.5 μg/mL (+), while the final concentration of rISG was 0.25 μg/mL (+) or 1.5 μg/mL (++). Using the gray intensity of PSMB5 pull-down by BTZ-b alone as a control, ImageJ software (NIH) was used to determine the levels of PSMB5 pull-down by BTZ-b with rISG competition. Numbers indicated on the lane. ( G ) BTZ binds to ISG20L2 as shown by SPR measurements. Graphs of equilibrium response unit (RU) responses versus compound concentrations were plotted. The estimated K D is 26.71 μM, as shown by the vertical dotted line. ( H ) Schematic mechanism of ISG20L2-induced MM BTZ resistance.
Proteasome β5 Subunit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psmb5+%CE%B25/PSMB5+Rabbit+mAb/pmc04933757-152-20-25
Average 93 stars, based on 1 article reviews
proteasome β5 subunit - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
anti β5  (Bethyl)
93
Bethyl anti β5
( A ) Molecular structure of biotinylated BTZ (BTZ-b). ( B ) Flow cytometry–based apoptosis assay to examine the cytotoxicity of BTZ-b in CTR-KD versus ISG-KD (sh1) ARD cells. The cells were treated with BTZ-b (2 μM) for 24 hours. DMSO- or biotin-treated cells served as CTRs ( n = 3). Student’s t test was performed. * P ≤ 0.05. ( C ) BTZ-b pull-down assay using ARD cell lysate in the presence of BTZ to examine BTZ competition with BTZ-b in <t>PSMB5</t> binding. BTZ was added to the cell lysate to a final concentration of 200 μM and incubated with BTZ-b–coated beads for competition. ( D ) Biotinylated BTZ pull-down assay using CTR-KD and ISG-KD ARD cell lysates. Biotin served as a negative control for pull-down. The pull-down precipitate and the whole-cell lysates (input) were subjected to Western blotting. ( E ) BTZ-b pull-down assay using CTR and ISG-OE AMO1 cell lysates. ( F ) BTZ-b pull-down assay using recombinant ISG20L2 (rISG) and PSMB5 (rB5) proteins. The recombinant protein was dissolved in PBS. The final concentration of rB5 was 0.5 μg/mL (+), while the final concentration of rISG was 0.25 μg/mL (+) or 1.5 μg/mL (++). Using the gray intensity of PSMB5 pull-down by BTZ-b alone as a control, ImageJ software (NIH) was used to determine the levels of PSMB5 pull-down by BTZ-b with rISG competition. Numbers indicated on the lane. ( G ) BTZ binds to ISG20L2 as shown by SPR measurements. Graphs of equilibrium response unit (RU) responses versus compound concentrations were plotted. The estimated K D is 26.71 μM, as shown by the vertical dotted line. ( H ) Schematic mechanism of ISG20L2-induced MM BTZ resistance.
Anti β5, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psmb5+%CE%B25/PSMB5+Antibody/10__1074_slash_jbc__m116__763128-190-30-38
Average 93 stars, based on 1 article reviews
anti β5 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
psmb5 β5 pw8895  (Proteintech)
93
Proteintech psmb5 β5 pw8895
( A ) Molecular structure of biotinylated BTZ (BTZ-b). ( B ) Flow cytometry–based apoptosis assay to examine the cytotoxicity of BTZ-b in CTR-KD versus ISG-KD (sh1) ARD cells. The cells were treated with BTZ-b (2 μM) for 24 hours. DMSO- or biotin-treated cells served as CTRs ( n = 3). Student’s t test was performed. * P ≤ 0.05. ( C ) BTZ-b pull-down assay using ARD cell lysate in the presence of BTZ to examine BTZ competition with BTZ-b in <t>PSMB5</t> binding. BTZ was added to the cell lysate to a final concentration of 200 μM and incubated with BTZ-b–coated beads for competition. ( D ) Biotinylated BTZ pull-down assay using CTR-KD and ISG-KD ARD cell lysates. Biotin served as a negative control for pull-down. The pull-down precipitate and the whole-cell lysates (input) were subjected to Western blotting. ( E ) BTZ-b pull-down assay using CTR and ISG-OE AMO1 cell lysates. ( F ) BTZ-b pull-down assay using recombinant ISG20L2 (rISG) and PSMB5 (rB5) proteins. The recombinant protein was dissolved in PBS. The final concentration of rB5 was 0.5 μg/mL (+), while the final concentration of rISG was 0.25 μg/mL (+) or 1.5 μg/mL (++). Using the gray intensity of PSMB5 pull-down by BTZ-b alone as a control, ImageJ software (NIH) was used to determine the levels of PSMB5 pull-down by BTZ-b with rISG competition. Numbers indicated on the lane. ( G ) BTZ binds to ISG20L2 as shown by SPR measurements. Graphs of equilibrium response unit (RU) responses versus compound concentrations were plotted. The estimated K D is 26.71 μM, as shown by the vertical dotted line. ( H ) Schematic mechanism of ISG20L2-induced MM BTZ resistance.
Psmb5 β5 Pw8895, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psmb5+%CE%B25/PSMB5+Antibody/pmc04051618-173-34-54
Average 93 stars, based on 1 article reviews
psmb5 β5 pw8895 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
anti-human psmb5/β5 antibody  (Biomol GmbH)
90
Biomol GmbH anti-human psmb5/β5 antibody
( A ) Molecular structure of biotinylated BTZ (BTZ-b). ( B ) Flow cytometry–based apoptosis assay to examine the cytotoxicity of BTZ-b in CTR-KD versus ISG-KD (sh1) ARD cells. The cells were treated with BTZ-b (2 μM) for 24 hours. DMSO- or biotin-treated cells served as CTRs ( n = 3). Student’s t test was performed. * P ≤ 0.05. ( C ) BTZ-b pull-down assay using ARD cell lysate in the presence of BTZ to examine BTZ competition with BTZ-b in <t>PSMB5</t> binding. BTZ was added to the cell lysate to a final concentration of 200 μM and incubated with BTZ-b–coated beads for competition. ( D ) Biotinylated BTZ pull-down assay using CTR-KD and ISG-KD ARD cell lysates. Biotin served as a negative control for pull-down. The pull-down precipitate and the whole-cell lysates (input) were subjected to Western blotting. ( E ) BTZ-b pull-down assay using CTR and ISG-OE AMO1 cell lysates. ( F ) BTZ-b pull-down assay using recombinant ISG20L2 (rISG) and PSMB5 (rB5) proteins. The recombinant protein was dissolved in PBS. The final concentration of rB5 was 0.5 μg/mL (+), while the final concentration of rISG was 0.25 μg/mL (+) or 1.5 μg/mL (++). Using the gray intensity of PSMB5 pull-down by BTZ-b alone as a control, ImageJ software (NIH) was used to determine the levels of PSMB5 pull-down by BTZ-b with rISG competition. Numbers indicated on the lane. ( G ) BTZ binds to ISG20L2 as shown by SPR measurements. Graphs of equilibrium response unit (RU) responses versus compound concentrations were plotted. The estimated K D is 26.71 μM, as shown by the vertical dotted line. ( H ) Schematic mechanism of ISG20L2-induced MM BTZ resistance.
Anti Human Psmb5/β5 Antibody, supplied by Biomol GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/psmb5+%CE%B25/psmb5++pw8895++antibody/pm24922589-147-4-10
Average 90 stars, based on 1 article reviews
anti-human psmb5/β5 antibody - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


( A ) Molecular structure of biotinylated BTZ (BTZ-b). ( B ) Flow cytometry–based apoptosis assay to examine the cytotoxicity of BTZ-b in CTR-KD versus ISG-KD (sh1) ARD cells. The cells were treated with BTZ-b (2 μM) for 24 hours. DMSO- or biotin-treated cells served as CTRs ( n = 3). Student’s t test was performed. * P ≤ 0.05. ( C ) BTZ-b pull-down assay using ARD cell lysate in the presence of BTZ to examine BTZ competition with BTZ-b in PSMB5 binding. BTZ was added to the cell lysate to a final concentration of 200 μM and incubated with BTZ-b–coated beads for competition. ( D ) Biotinylated BTZ pull-down assay using CTR-KD and ISG-KD ARD cell lysates. Biotin served as a negative control for pull-down. The pull-down precipitate and the whole-cell lysates (input) were subjected to Western blotting. ( E ) BTZ-b pull-down assay using CTR and ISG-OE AMO1 cell lysates. ( F ) BTZ-b pull-down assay using recombinant ISG20L2 (rISG) and PSMB5 (rB5) proteins. The recombinant protein was dissolved in PBS. The final concentration of rB5 was 0.5 μg/mL (+), while the final concentration of rISG was 0.25 μg/mL (+) or 1.5 μg/mL (++). Using the gray intensity of PSMB5 pull-down by BTZ-b alone as a control, ImageJ software (NIH) was used to determine the levels of PSMB5 pull-down by BTZ-b with rISG competition. Numbers indicated on the lane. ( G ) BTZ binds to ISG20L2 as shown by SPR measurements. Graphs of equilibrium response unit (RU) responses versus compound concentrations were plotted. The estimated K D is 26.71 μM, as shown by the vertical dotted line. ( H ) Schematic mechanism of ISG20L2-induced MM BTZ resistance.

Journal: JCI Insight

Article Title: ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5

doi: 10.1172/jci.insight.157081

Figure Lengend Snippet: ( A ) Molecular structure of biotinylated BTZ (BTZ-b). ( B ) Flow cytometry–based apoptosis assay to examine the cytotoxicity of BTZ-b in CTR-KD versus ISG-KD (sh1) ARD cells. The cells were treated with BTZ-b (2 μM) for 24 hours. DMSO- or biotin-treated cells served as CTRs ( n = 3). Student’s t test was performed. * P ≤ 0.05. ( C ) BTZ-b pull-down assay using ARD cell lysate in the presence of BTZ to examine BTZ competition with BTZ-b in PSMB5 binding. BTZ was added to the cell lysate to a final concentration of 200 μM and incubated with BTZ-b–coated beads for competition. ( D ) Biotinylated BTZ pull-down assay using CTR-KD and ISG-KD ARD cell lysates. Biotin served as a negative control for pull-down. The pull-down precipitate and the whole-cell lysates (input) were subjected to Western blotting. ( E ) BTZ-b pull-down assay using CTR and ISG-OE AMO1 cell lysates. ( F ) BTZ-b pull-down assay using recombinant ISG20L2 (rISG) and PSMB5 (rB5) proteins. The recombinant protein was dissolved in PBS. The final concentration of rB5 was 0.5 μg/mL (+), while the final concentration of rISG was 0.25 μg/mL (+) or 1.5 μg/mL (++). Using the gray intensity of PSMB5 pull-down by BTZ-b alone as a control, ImageJ software (NIH) was used to determine the levels of PSMB5 pull-down by BTZ-b with rISG competition. Numbers indicated on the lane. ( G ) BTZ binds to ISG20L2 as shown by SPR measurements. Graphs of equilibrium response unit (RU) responses versus compound concentrations were plotted. The estimated K D is 26.71 μM, as shown by the vertical dotted line. ( H ) Schematic mechanism of ISG20L2-induced MM BTZ resistance.

Article Snippet: Recombinant human ISG20L2 protein was custom-made by Merry Bio Technology Co., Ltd. Western blot antibodies against PSMB5 (catalog sc-393931), PSMD8 (catalog sc-514053), PSMD3 (catalog sc-393588), PSMC5 (catalog sc-390631), and eIF2a (catalog sc-133132) were purchased from Santa Cruz Biotechnology.

Techniques: Flow Cytometry, Apoptosis Assay, Pull Down Assay, Binding Assay, Concentration Assay, Incubation, Negative Control, Western Blot, Recombinant, Control, Software